Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK2 | P24941 | 8/20 | 0.47 |
| ▸ | GSK3B | P49841 | 7/20 | 0.47 |
| ▸ | CYP19A1 | P11511 | 2/20 | 0.40 |
| ▸ | NAMPT | P43490 | 1/20 | 0.39 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.36 |
| ▸ | CCNA1 | P78396 | 1/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.36 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.36 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13120630 | 0.91 | CDK2 (0.59) | CDK2GSK3BCYP19A1CCNA2CCNA1 | |
| SCHEMBL12954278 | 0.91 | CDK2 (0.52) | CDK2GSK3BCYP19A1CCNA2CCNA1 | |
| SCHEMBL13289431 | 0.88 | CDK2 (0.49) | CDK2GSK3BCYP19A1CCNA2CCNA1 | |
| SCHEMBL13289419 | 0.88 | CDK2 (0.41) | CDK2GSK3BCYP1A2CYP2D6CYP2C19 | |
| SCHEMBL13120677 | 0.87 | CDK2 (0.62) | CDK2GSK3BCCNA2CCNA1 | |
| SCHEMBL13288977 | 0.86 | CDK2 (0.47) | CDK2GSK3BCYP19A1NAMPT | |
| SCHEMBL13288974 | 0.86 | CDK2 (0.52) | CDK2GSK3BCCNA2CCNA1 | |
| SCHEMBL13288973 | 0.85 | CDK2 (0.48) | CDK2GSK3BCYP19A1CCNA2CCNA1 | |
| SCHEMBL14607112 | 0.84 | CDK2 (0.46) | CDK2GSK3BCYP19A1CCNA2CCNA1 | |
| SCHEMBL13288958 | 0.84 | GSK3B (0.46) | CDK2GSK3B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2194058-A1 | Pyrazolopyrimidines suitable for the treatment of cancer diseases | SCHERING CORPORATION (US) | 2010-06-09 | — | — | EP | disclosed |
| US-20070054906-A1 | Novel pyrazolopyrimidines as cyclin dependent kinase inhibitors | SCHERING CORPORATION | 2007-03-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070054906-A1 | Novel pyrazolopyrimidines as cyclin dependent kinase inhibitors | CDK2, CDK1, CDKN1A | CDK2 1/4885GSK3B 695/4885CYP19A1 1071/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.